- Becton Dickinson’s adjusted EPS for the first quarter was $3.43, surpassing the estimate of $2.97.
- Total revenue reported was $5.17 billion, which exceeded the projected $5.09 billion.
- Medical segment revenue amounted to $2.62 billion.
- Revenue from Medication Delivery Solutions was $1.12 billion, above the estimate of $1.08 billion.
- Medication Management Solutions revenue missed the estimate slightly, recording $801 million against an anticipated $802.7 million.
- Pharmaceutical Systems revenue came in at $418 million, underperforming the estimate of $430 million.
- Life Sciences revenue hit $1.30 billion, just over the expected $1.29 billion.
- Biosciences revenue was slightly below estimates at $361 million compared to an expected $361.6 million.
- Interventional segment revenue was $1.26 billion, surpassing the estimate of $1.24 billion.
- Surgery revenue exceeded expectations at $395 million, compared to an estimate of $378.7 million.
- Peripheral Intervention revenue slightly outperformed with $473 million against a forecast of $470.8 million.
- Urology and Critical Care revenue matched closely with the estimate, recording $389 million versus $389.6 million projected.
- The company revised its fiscal 2025 guidance upward due to robust performance in the first quarter and a positive full-year outlook.
- Becton Dickinson increased its full-year adjusted diluted EPS guidance at the midpoint, factoring in currency translation effects.
- Current analyst recommendations include 16 buys and 2 holds, with no sells reported.
“`
A look at Becton Dickinson and Co Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 2 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Becton Dickinson and Co seems to have a promising long-term outlook. With solid scores in Growth, Value, and Dividend, the company demonstrates a balanced performance across key factors. Especially noteworthy is the high Momentum score, indicating strong market traction and positive investor sentiment for the company. Despite a slightly lower score in Resilience, Becton Dickinson and Co‘s overall outlook appears positive, positioning it well in the competitive landscape of the medical technology industry.
Becton, Dickinson and Company, a global player in the medical technology sector, is focused on producing and selling a range of medical devices, instrument systems, and reagents. The company caters to various segments including healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. With a diverse customer base and a commitment to innovation, Becton Dickinson and Co‘s Smartkarma Smart Scores reflect a company with solid growth prospects and a strong market presence.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
